Search Results

You are looking at 101 - 110 of 1,128 items for :

  • "characteristics" x
  • All content x
Clear All
Full access

Willemieke P.M. Dijksterhuis, Anouk E.J. Latenstein, Jessy Joy van Kleef, Rob H.A. Verhoeven, Jeanne H.M. de Vries, Marije Slingerland, Elles Steenhagen, Joos Heisterkamp, Liesbeth M. Timmermans, Marian A.E. de van der Schueren, Martijn G.H. van Oijen, Sandra Beijer, and Hanneke W.M. van Laarhoven

is provided by the patient. 27 Data on patient and tumor characteristics, treatment, and survival were extracted from the Netherlands Cancer Registry (NCR), which is a population-based registry that covers the total Dutch population of >17 million

Full access

Vinayak Muralidhar, Paul L. Nguyen, Brandon A. Mahal, David D. Yang, Kent W. Mouw, Brent S. Rose, Clair J. Beard, Jason A. Efstathiou, Neil E. Martin, Martin T. King, and Peter F. Orio III

PSA levels ≥98.0 ng/mL are grouped together without further granularity regarding the exact PSA level. Median age and follow-up were compared using the Kruskal-Wallis test; other baseline patient characteristics were compared using the chi-square test

Full access

Matthew G. Fury, Eric Sherman, Donna Lisa, Neeraj Agarwal, Kenneth Algazy, Bruce Brockstein, Corey Langer, Dean Lim, Ranee Mehra, Sandeep K. Rajan, Susan Korte, Brynna Lipson, Furhan Yunus, Tawee Tanvetyanon, Stephanie Smith-Marrone, Kenneth Ng, Han Xiao, Sofia Haque, and David G. Pfister

more of the first 18 patients (each group treated separately) experienced a dose-limiting toxicity (as defined in the protocol) during cycle 1 or 2, that group would be closed because of excess toxicity. Results Patient Characteristics The

Full access

Min Huang, Joyce O’Shaughnessy, Jing Zhao, Amin Haiderali, Javier Cortes, Scott Ramsey, Andrew Briggs, Vassiliki Karantza, Gursel Aktan, Cynthia Z. Qi, Chenyang Gu, Jipan Xie, Muhan Yuan, John Cook, Michael Untch, Peter Schmid, and Peter A. Fasching

4 RCTs, carboplatin in 3 RCTs, and nab-paclitaxel, everolimus, and anthracycline in 1 RCT each. Different pCR definitions were used across trials, of which ypT0/is ypN0 was the most common. The characteristics of the included trials are listed in

Full access

Amy A. Kirkham, Karen A. Gelmon, Cheri L. Van Patten, Kelcey A. Bland, Holly Wollmann, Donald C. McKenzie, Taryne Landry, and Kristin L. Campbell

Baseline characteristics were compared between groups using independent t tests and chi-square tests. Relative risk (RR; with 95% confidence intervals and number needed to treat [NNT]) was used to compare categorical metrics of treatment tolerance

Full access

Lucas K. Vitzthum, Chris Straka, Reith R. Sarkar, Rana McKay, J. Michael Randall, Ajay Sandhu, James D. Murphy, and Brent S. Rose

year before PCa diagnosis as previously described. 15 , 16 Table 1. Patient and Tumor Characteristics Information on treatment with ADT was obtained from the VA pharmacy database. CAB was defined as treatment with a nonsteroidal androgen receptor

Full access

Jeffrey M. Martin, Tianyu Li, Matthew E. Johnson, Colin T. Murphy, Alan G. Howald, Marc C. Smaldone, Alexander Kutikov, David Y.T. Chen, Rosalia Viterbo, Richard E. Greenberg, Robert G. Uzzo, and Eric M. Horwitz

univariate analyses were performed. Results From 2003 to 2011, 475 patients received PPRT at FCCC (83 adjuvant and 392 salvage). The patient characteristics and descriptives are listed in Table 1 . Patients were more likely to receive adjuvant RT if

Full access

Arif Kamal, Tian Zhang, Steve Power, and P. Kelly Marcom

patients with cancer and the noncancer control population, a chi-square test was performed. Univariate logistic regression was used to determine patient and disease characteristics associated with the ordering of imaging. For determination of the attribute

Full access

Eric J. Roeland, Kathryn J. Ruddy, Thomas W. LeBlanc, Ryan D. Nipp, Gary Binder, Silvia Sebastiani, Ravi Potluri, Luke Schmerold, Eros Papademetriou, Lee Schwartzberg, and Rudolph M. Navari

We analyzed patient characteristics, HEC courses, and clinician practice patterns using descriptive statistics. Clinician HEC CINV prophylaxis adherence was categorized into deciles for each HEC, noting the clinicians with ≤90% adherence. Variability

Full access

Emily C. Harrold, Ahmad F. Idris, Niamh M. Keegan, Lynda Corrigan, Min Yuen Teo, Martin O’Donnell, Sean Tee Lim, Eimear Duff, Dearbhaile M. O’Donnell, M. John Kennedy, Sue Sukor, Cliona Grant, David G. Gallagher, Sonya Collier, Tara Kingston, Ann Marie O’Dwyer, and Sinead Cuffe

independent predictors of insomnia syndrome. Results Demographic and Clinical Characteristics Of the 337 patients invited to participate, 87% consented to study inclusion (n=294); 12 declined without explanation, 15 were too unwell to participate, 8 declined